A general model for the estimation of societal costs of lost production and informal care in Italy
DOI:
https://doi.org/10.7175/fe.v18i1.1278Keywords:
Indirect cost, Health-Related Quality of Life, Societal perspective, Yearly production valueAbstract
We developed a general model for estimating and comparing disease- and treatment-specific lost paid/unpaid production (due to premature death and reduced ability) and informal care received (due to reduced ability) in Italy, starting from survival, demographic and Health-Related Quality of Life (HRQoL) data. Assuming the disease is not selecting a systematically different population in terms of mean wage than the general public, age- and gender-specific yearly production values are estimated combining data from the last Italian Time-Use-Survey on time dedicated to paid and unpaid (household, caring and volunteering) activities, with a) the last Italian Wage-Structure-Survey, for paid activities (Human Capital approach), and b) market prices for an equivalent service, for unpaid production (Proxy Good approach). To avoid double counting, age- and gender-specific maximum care needs are approximated with time dedicated to eating and personal care,reported in TUS. Present monetary values of future productivity and informal care are estimated applying a 3.5% annual discount rate. Lost life years due to a particular condition/treatment are estimated by comparison of its survival curve with the corresponding age- and gender-normalized survival curve of the general Italian population. The degrees of reduced productivity and need for informal care for remaining life years are estimated by comparison of condition-/treatment-specific
reported HRQoL data with demographically matched Italian norms. Our results will be useful for cost-effectiveness and budget impact analyses conducted from the perspective of the Italian society and we encourage the inclusion of these costs in economic evaluations to allow decision makers to be fully informed about the costs and consequences of their decisions on healthcare interventions.
References
CIPE, Inter-Ministerial Committee for Economic Planning. Identifying criteria for contracting on the price of innovative medicines. Decree of January 30, 1997. Official Gazzette
Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the Economic Evaluation in Health Care Programmes (2nd ed.). New York: Oxford University Press, 1997
Van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Labour and health status in economic evaluation of health care: The Health Labour Questionnaire. Int J Technol Assess Health Care 1996; 12: 405-15; https://doi.org/10.1017/S0266462300009764
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol 2014; 20: 327-37; https://doi.org/10.3350/cmh.2014.20.4.327
Colombo F, Llena-Nozal A, Mercier J, et al. Help wanted? Providing and paying for long-term care. Paris: OECD Publishing; 2011
Riedel M, Kraus M. Informal care provision in Europe: regulation and profile of providers. ENEPRI Research Report no. 96 (2011). Available at: https://www.ceps.eu/publications/informal-care-provision-europe-regulation-and-profile-providers (last accessed December 2016)
Clark AM, Reid ME, Morrison CE, et al. The complex nature of informal care in homebased heart failure management. J Adv Nursing 2008; 61: 373-83; https://doi.org/10.1111/j.1365-2648.2007.04527.x
Knowlton AR, Arnsten JH, Gourevitch MN, et al. Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: The role of informal caregiving and household factors. JAIDS 2007; 46: S110-9; https://doi.org/10.1097/QAI.0b013e31815767f8
Clark RE, Xie H, Adachi-Mejia AM, et al. Substitution between formal and informal care for persons with severe mental illness and substance use disorders. J Ment Health Policy Econ 2001; 4: 123-32
Jiménez-Martin S, Prieto CV. The trade-off between formal and informal care in Spain. Eur J Health Econ 2012; 13: 461-90; https://doi.org/10.1007/s10198-011-0317-z
Weaver FM, Weaver BA. Does availability of informal care within the household impact hospitalisation? Health Econ Policy Law 2014; 9: 71-93
Krol M, Papenburg J, Koopmanschap M, et al. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 2011; 29: 601-19
van den Berg B, Brouwer WB, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ 2004; 5: 36-45; https://doi.org/10.1007/s10198-003-0189-y
Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. PharmacoEconomics 2013; 31: 1105-19; https://doi.org/10.1007/s40273-013-0104-z
Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inform J 2001; 35: 189-201; https://doi.org/10.1177/009286150103500122
Fattore G, Jommi C. La determinazione del prezzo dei farmaci innovativi in Italia registrati con procedura centralizzata europea. Mecosan 1997; 22: 103-11
Garattini L, Tediosi F, Ghislandi S, et al. How Do Italian Pharmacoeconomists Evaluate Indirect Costs? Value in Health 2000; 3: 270-6; https://doi.org/10.1046/j.1524-4733.2000.34004.x
Weisbrod BA. The valuation of human capital. J Polit Econ 1961; 69: 425-36; https://doi.org/10.1086/258535
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014; 32: 335-44; https://doi.org/10.1007/s40273-014-0132-3
ISTAT – The National Institute for Statistics. Uso del tempo, 2012. Available at: http://www.istat.it/it/archivio/52079 (last accessed December 2016)
ISTAT – The National Institute for Statistics. Tavole di mortalità 2015. Available at: http://demo.istat.it/index.html (last accessed December 2016)
ISTAT – The National Institute for Statistics. Struttura delle retribuzioni, 2013. Available at: http://www.istat.it/it/archivio/83362 (last accessed December 2016)
Associazione Domina. CCNL Domestico. Available at: http://www.colfdomina.it/ccnl/ (last accessed December 2016)
CNEL. La valorizzazione economica del lavoro volontario nel settore non profit, 2011. Available at: http://www.cnel.it/29?shadow_ultimi_aggiornamenti=3333 (last accessed December 2016)
Szende A, Janssen B, Cabases J. Self-Reported Population Health: An International Perspective based on EQ-5D, 2014
The EuroQol Group. EuroQol, a new facility for the measurement of healthrelated quality of life. Health Policy 1990; 16: 199-208; https://doi.org/10.1016/0168-8510(90)90421-9
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142-52; https://doi.org/10.1056/NEJMoa1411321
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76; https://doi.org/10.1093/jnci/85.5.365
Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol 2011; 87: 330-7; https://doi.org/10.1111/j.1600-0609.2011.01665.x
Leleu X, Petrucci MT, Welslau M, et al. Psychometric performance of the EORTC Quality of Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) in relapsed/refractory multiple myeloma (RRMM). Blood 2013; 122: 1721
Wisløff F, Eika S, Hippe E, et al. Measurement of health related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996; 92: 604-13; https://doi.org/10.1046/j.1365-2141.1996.352889.x
Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual (ed 3). Brussels: European Organisation for Research and Treatment of Cancer, 2001
Stewart AK, Dimopoulos MA, Masszi T, et al. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol 2016; 34: 3921-30; https://doi.org/10.1200/jco.2016.66.9648
Jakubowiak AJ, Campioni M, Benedict Á, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ 2016; 19: 1061-107; https://doi.org/10.1080/13696998.2016.1194278
AIRTUM ITACAN – Italian Association of Cancer Registries. Tumori in Italia, Versione 2.0. Available at: http://www.registri-tumori.it/ (last accessed December 2016)
Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89; https://doi.org/10.1016/0167-6296(94)00044-5
Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005-10; https://doi.org/10.1016/0277-9536(92)90131-9
Oliva-Moreno J. Loss of Labour Productivity Caused by Disease and Health Problems: What is the Magnitude of its Effect on Spain’s Economy? Eur J Health Econ 2012; 13: 605-14; https://doi.org/10.1007/s10198-011-0344-9
ISTAT – The National Institute for Statistics. Bilancio demografico 2015. Available at: http://dati.istat.it/Index.aspx (last accessed December 2016)
ISTAT – The National Institute for Statistics. Principali aggregati del Prodotto interno lordo. Available at: http://dati.istat.it/ (last accessed December 2016)
Chari AV, Engberg J, Ray KN, et al. The Opportunity Costs of Informal Elder-Care in the United States: New Estimates from the American Time Use Survey. Health Serv Res 2015; 50: 871-82
Arno PS, Levine C, Memmott MM. The economic value of informal caregiving. Health Aff (Millwood) 1999; 18: 182-8; https://doi.org/10.1377/hlthaff.18.2.182
Oliva-Moreno J, Pe-a-Longobardo LM, Vilaplana-Prieto C. An estimation of the value of informal care provided to dependent people in Spain. Appl Health Econ Health Policy 2015; 13: 223-31; https://doi.org/10.1007/s40258-015-0161-x
Hollander MJ, Liu G, Chappell NL. Who Cares and How Much? The Imputed Economic Contribution to the Canadian Healthcare System of Middle-Aged and Older Unpaid Caregivers Providing Care to The Elderly. Healthc Q 2009; 12: 42-9; https://doi.org/10.12927/hcq.2009.20660
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
